HOME >> MEDICINE >> NEWS
EVEREST data on use of tolvaptan published in JAMA and featured at ACC

PRINCETON, N.J., March 25, 2007-- Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) published in the March 28 issue of the Journal of the American Medical Association (JAMA). These data were presented at the American College of Cardiology's 56th Annual Scientific Sessions (ACC).

The phase 3 EVEREST trial, involving a total of 4,133 ADHF patients, represents three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient care or discharge, whichever came first.

Data from the two short-term studies documented that tolvaptan treatment yielded significantly greater improvements than placebo based on the primary endpoint (study A: p less than 0.001 and study B: p less than 0.001), which was the composite score of changes in patient-assessed global clinical status and changes in body weight at day seven or discharge. Long-term tolvaptan use did not differ from placebo on either of the study's two primary endpoints: deaths from all causes (p equal to 0.68) or from the combined endpoint of cardiovascular (CV) deaths or subsequent hospitalization for worsening HF (p equal to 0.55).

"Tolvaptan exhibited short-term symptomatic benefits in patients hospitalized with worsening heart failure," said investigator Marvin A. Konstam, M.D., chief of the Division of Cardiology at the Tufts- New England
'"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Porter Novelli
27-Mar-2007


Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... New York (PRWEB) , ... August 23, 2017 , ... ... intellectual and developmental disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people ... just the first organization of its kind in the state of New Jersey – ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Jachimowicz ... California, office at 1530 The Alameda, Suite 115. The office is located between Schiele ... the contact information remains the same. Clients can still call the office at 408-246-5500. ...
(Date:8/23/2017)... Texas (PRWEB) , ... August 23, 2017 , ... This ... denied claims firms in Texas. Founded by Bill Voss, the firm grew quickly and ... decade and a half of helping clients get the money they deserve from their ...
(Date:8/23/2017)... ... 2017 , ... Loyale Healthcare today announced the ... joins other recent high-profile hires including Frank Massi, Chief Revenue Officer and Shirley ... helping physician practices and hospitals automate their clinical and financial processes to gain ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
Breaking Medicine News(10 mins):
(Date:8/23/2017)... 23, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... with domestic and non-U.S. investors for the sale ... shares of the Company,s newly designated Series B ... Current shareholders accounted for 58% of the securities ...
(Date:8/23/2017)... -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing ... epilepsy, announced today that the U.S. Food and Drug ... the treatment of patients with Dravet Syndrome. Dravet Syndrome ... of the Food, Drug, and Cosmetic Act. ... of epilepsy, begins in the first year of life ...
(Date:8/18/2017)... , Aug. 18, 2017  Nortis today announced the awarding of a $688K ... for the third year of a Small Business Innovation ... Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ParVivo Chip ... ...
Breaking Medicine Technology:
Cached News: